Illumina, Inc. (ILMN) Position Increased by LS Investment Advisors LLC

LS Investment Advisors LLC boosted its stake in Illumina, Inc. (NASDAQ:ILMN) by 12.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,580 shares of the life sciences company’s stock after acquiring an additional 402 shares during the period. LS Investment Advisors LLC’s holdings in Illumina were worth $782,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. lifted its position in Illumina by 1.0% during the fourth quarter. Oppenheimer & Co. Inc. now owns 89,689 shares of the life sciences company’s stock valued at $19,596,000 after buying an additional 860 shares during the period. Biondo Investment Advisors LLC lifted its position in Illumina by 3.8% during the fourth quarter. Biondo Investment Advisors LLC now owns 45,280 shares of the life sciences company’s stock valued at $9,893,000 after buying an additional 1,670 shares during the period. Daiwa Securities Group Inc. lifted its position in Illumina by 4.3% during the fourth quarter. Daiwa Securities Group Inc. now owns 5,543 shares of the life sciences company’s stock valued at $1,211,000 after buying an additional 229 shares during the period. California Public Employees Retirement System lifted its position in Illumina by 13.2% during the fourth quarter. California Public Employees Retirement System now owns 350,849 shares of the life sciences company’s stock valued at $76,657,000 after buying an additional 40,809 shares during the period. Finally, Teacher Retirement System of Texas lifted its position in Illumina by 1,370.7% during the fourth quarter. Teacher Retirement System of Texas now owns 62,358 shares of the life sciences company’s stock valued at $13,625,000 after buying an additional 58,118 shares during the period. Institutional investors and hedge funds own 92.04% of the company’s stock.

In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $211.35, for a total value of $4,227,000.00. Following the completion of the transaction, the director now owns 531,717 shares of the company’s stock, valued at approximately $112,378,387.95. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $225.33, for a total value of $32,672.85. Following the completion of the transaction, the senior vice president now directly owns 6,388 shares of the company’s stock, valued at approximately $1,439,408.04. The disclosure for this sale can be found here. In the last three months, insiders sold 114,440 shares of company stock valued at $25,318,904. 0.89% of the stock is owned by insiders.

Illumina, Inc. (NASDAQ:ILMN) opened at $223.11 on Thursday. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.99 and a quick ratio of 3.55. The stock has a market capitalization of $32,404.68, a PE ratio of 54.97, a PEG ratio of 2.91 and a beta of 0.92. Illumina, Inc. has a 52-week low of $158.02 and a 52-week high of $248.97.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.22. Illumina had a return on equity of 21.52% and a net margin of 26.56%. The business had revenue of $778.00 million during the quarter, compared to analyst estimates of $752.04 million. During the same quarter in the previous year, the firm earned $0.85 EPS. Illumina’s revenue was up 25.7% on a year-over-year basis. research analysts expect that Illumina, Inc. will post 4.59 earnings per share for the current year.

Several equities analysts have commented on ILMN shares. Barclays raised their price objective on Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 25th. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $229.00 price objective for the company in a research report on Friday, October 27th. Janney Montgomery Scott raised Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd. Robert W. Baird raised Illumina from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $184.00 to $228.00 in a research report on Wednesday, October 25th. Finally, Wells Fargo & Co reissued a “positive” rating and set a $260.00 price objective (up previously from $250.00) on shares of Illumina in a research report on Tuesday, January 9th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $241.39.

TRADEMARK VIOLATION WARNING: This news story was reported by Week Herald and is owned by of Week Herald. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://weekherald.com/2018/02/15/illumina-inc-ilmn-position-increased-by-ls-investment-advisors-llc.html.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply